Except the keynote speeches, the NZBCS-2021 programme also consists of up to 80 standard and short talks, many e-Poster presentations, as well as several sessions of new product/technical introduction. The e-posters publish the findings of those who cannot give an oral presentation due to the time constraint of the meeting. It also serves as a complementary format of dissemination for the oral talks.
In addition, there will be a session dedicated to breast cancer charitable or government organisations and support services to promote and acknowledge their support for research and those affected by breast cancer.
We are calling for abstracts that cover a wide range of the topics about the research on breast cancer. They include, but not limited to, the following:
Epidemic & Precision Prevention
Screening & Early Detection
Breast Cancer Pathological and Molecular Stratifications
Professor Ian Ellis is Professor of Cancer Pathology, Nottingham University and an Honorary Consultant Pathologist at the Nottingham City Hospital. He has been involved in the practice of pathology for 35 years and has an international reputation in clinical and translational research in breast disease, particularly classification and molecular pathology of breast cancer and evaluation of prognostic factors. He is author of over 700 peer reviewed scientific publications, chapters in medical textbooks and specialist textbooks in pathology and an experienced lecturer being a founder member of the faculty of the Nottingham Blamey International Breast Education Centre. His H Index is 104.
He is a Past President of the Pathological Society of Great Britain and Ireland. He has been Specialty Advisor to The Royal College of Pathologists, and is past Chairman of the UK National Co-ordinating Committee for Breast Pathology. He has acted as an advisor to the DoH, UICC, WHO and IARC. He is Medical Director of Source Bioscience plc. He retired from his full time University and honorary NHS consultant post at the end of August 2015, returning on a part time basis in October 2015.
He was named in 2010 as one of the top 20 most influential people in the field of breast cancer research in the world and one of just four UK scientists in the list compiled from a field of 44,000 scientists around the globe; as No 8 in the top 100 most influential laboratory medicine professionals in the World in a survey carried out by The Pathologist in 2015; and as one of the top 100 Pathologists Worldwide by The Pathologist in The Pathologist’s Power List 2018. His other awards included Honorary Fellowship of the Royal College of Pathologists of Australia in 2011, The Presidents Medal, British Division of the International Academy of Pathology in 2014, NHS Clinical Excellence Award – Platinum in 2015, The Ritchie Medal by the Pathological Society of Great Britain and Ireland in 2016, and first recipient of the BCRF-Larry Norton Award for Excellence in Breast Pathology by the International Society of Breast Pathology in 2018.
More information about Professor Ian Ellis can be found here.
Prof Mike Eccles is professor at the University of Otago, New Zealand and the New Zealand Institute for Cancer Research Trust Chair in Cancer Pathology. He serves in the Steering Committees of a variety of scientific organisatioins, including Genetics Otago, Centre for Reproduction and Genomics, and Health Research South Board. He specialise in molecular cancer research, with expertise in cancer genetics, human molecular genetics, and developmental genetics. His research background involves gene and chromosome mapping, epigenetic studies of gene regulation, and impacts on cell behaviour of gene expression. He heads the Developmental Genetics and Pathology Laboratory in the Pathology Department, Dunedin School of Medicine, and am currently very interested in genetic, environmental, and epigenetic mechanisms of cancer in relation to developmental biology and cancer / overgrowth diseases.
More information about Prof Mike Eccles can be found here.
Prof Jane Visvader is joint head of the ACRF Cancer Biology and Stem Cells Division at the Walter and Eliza Hall Institute (WEHI). She obtained her PhD at the University of Adelaide. Following postdoctoral work at the Salk Institute and the WEHI, she took an appointment as a Harvard Medical School Instructor in Boston before she was recruited back by the prestigious Victorian Breast Cancer Research Consortium (VBCRC) to establish a Breast Cancer Laboratory.
Over the past two decades, Prof Visvader’s team have made important contributions to the mammary biology and breast cancer fields by isolating mammary stem cells, defining master regulators of mammary gland development and identifying genetic lesions that drive oncogenesis. In 2006, her team published a milestone study in Nature describing the successful isolation of the long-sought mouse mammary stem cell. In other work, it was revealed that breast stem cells are highly responsive to steroid hormone signalling, despite lacking hormone receptors, thus explaining the long-established epidemiological link between hormone exposure and breast cancer. Several master regulators that orchestrate cell fate decisions in the mammary gland have also been defined, providing an indispensable framework for understanding mammary lineage commitment and differentiation. Her group subsequently proved the existence of an analogous hierarchy in human breast and derived unique gene signatures for the different subpopulations. This work led to the discovery that aberrant luminal progenitors, rather than stem cells, are the transformation target in BRCA1- associated basal tumours. More recently, their extensive bank of human breast cancer xenografts has begun to serve as excellent preclinical models for testing new therapeutic drug combinations for the treatment of breast cancer.
Prof Visvader is a Fellow of the Australian Academy of Science and the recipient of a NHMRC Australia Fellowship. She has received many prestigious awards, including the Tschira Stiftung Lectureship (German Cancer Centre), the Royal Society of Victoria Medal for Excellence in Research, and the Brinker Award for Scientific Distinction in Basic Science (joint award). She was also awarded the Lemberg Medal by the Australian Society for Biochemistry and Molecular Biology in 2016.
More information about Prof Jane Visvader can be found here.
Professor Ross Lawrenson, MBBS London, MD London, FRCGP, FFPH FAFPHM
Professor Ross Lawrenson is Professor of Population Health at the University of Waikato, New Zealand. He is an epidemiologist and public health physician, whose main research interest is identifying ways of improving outcomes for cancer. He has worked both in the United Kingdom and in New Zealand as an academic and health services researcher. He has published a textbook on Epidemiology and Public Health Medicine and authored over 180 peer-reviewed papers. He is a former Chair of the National Screening Advisory Committee and a board member of the New Zealand Cancer Health Information Strategy and PHARMAC committees.
More information about Professor Ross Lawrenson can be found here.
Professor Sarah-Jane Dawson, MBBS (Hons), FRACP, PhD (Cantab)
Professor Sarah-Jane Dawson is a clinician-scientist at Peter MacCallum Cancer Centre & The University of Melbourne, Australia. She obtained her medical degree from the University of Melbourne in 1998, and trained as a medical oncologist in Melbourne, Australia. She completed her PhD at the University of Cambridge, UK. Following postdoctoral studies at the Cancer Research UK Cambridge Institute, she returned to Melbourne in 2014 to head the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre. She also holds a joint appointment with the Centre of Cancer Research at The University of Melbourne (since 2016) and currently holds a CSL Centenary Fellowship (2018-2022). Her current research interests are focused on the development of noninvasive blood-based biomarkers ('liquid biopsies') for clinical application, including early detection, risk stratification and disease monitoring in cancer management.
More information about Professor Sarah-Jane Dawson can be found here.
Prof Ian Campbell is co-Head of the Cancer Genomics and Genetics Program at the Peter MacCallum Cancer Centre and Professor in the Sir Peter MacCallum Department of Oncology at the University of Melbourne, Australia. Professor Campbell’s laboratory is regarded as one of Australia’s leading breast and ovarian cancer genetics facilities. His laboratory has particular international recognition for work on the discovery of new familial breast and ovarian cancer predisposition genes through exome sequencing and large scale targeted sequencing approaches.
Professor Campbell has also made a series of seminal contributions to the understanding of the etiology of ovarian cancer and continues a leading international role into somatic molecular analyses of breast and ovarian cancer precursor lesions. He is the lead investigator of Lifepool, which is a cohort of 54,000 women attending Breast Screening services. Lifepool (www.lifepool.org) provides an internationally unique resource capable of providing definitive answers to critical questions in breast cancer epidemiology and biology.
More information about Prof Ian Campbell can be found here.